Catalog No.:AA001BYD

1401090-53-6 | Ibiglustat

Name: Name:Ibiglustat
Brand: AABLOCKS
SKU: AA001BYD
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

5mg

98%

in stock

$108.00 $76.00

- +

25mg

≥98%

in stock

$183.00 $128.00

- +

50mg

95%

in stock

$331.00 $232.00

- +

100mg

98%

in stock

$497.00 $348.00

- +

250mg

95%

in stock

$728.00 $510.00

- +

98%

in stock

$2,172.00 $1,520.00

- +

Technical Information
Properties
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA001BYD

Chemical Name:

Ibiglustat

CAS Number:

1401090-53-6

Molecular Formula:

C20H24FN3O2S

Molecular Weight:

389.4869

MDL Number:

MFCD28502073

SMILES:

O=C(NC(c1csc(n1)c1ccc(cc1)F)(C)C)O[C@@H]1CN2CCC1CC2

Properties

Computed Properties

Complexity:

533

Covalently-Bonded Unit Count:

Defined Atom Stereocenter Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

XLogP3:

3.5

Downstream Synthesis Route

97-67-6

1401090-53-6

(S)-quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamatemalate

[1]CurrentPatentAssignee:SANOFI-WO2014/152215,2014,A1Locationinpatent:Page/Pagecolumn48;49

C13H11FN2OS

(S)-quinuclidin-3-ol

1401090-53-6

[1]CurrentPatentAssignee:SANOFI-US9126993,2015,B2Locationinpatent:Page/Pagecolumn92

[2]CurrentPatentAssignee:SANOFI-WO2014/152215,2014,A1Locationinpatent:Page/Pagecolumn46;47

[3]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1Locationinpatent:Page/Pagecolumn26

[4]Zhao,Jin;Gimi,Rayomand;Katti,Sanjeev;Reardon,Michael;Nivorozhkin,Vitaly;Konowicz,Paul;Lee,Edward;Sole,Lynne;Green,Jerome;Siegel,CraigS.[OrganicProcessResearchandDevelopment,2015,vol.19,#5,p.576-581]

[5]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1Locationinpatent:Page/Pagecolumn95;96

[6]CurrentPatentAssignee:SANOFI-WO2020/163337,2020,A1Locationinpatent:Page/Pagecolumn88;92-94

[7]CurrentPatentAssignee:SANOFI-WO2020/163244,2020,A1Locationinpatent:Page/Pagecolumn76;80-81

[8]CurrentPatentAssignee:SANOFI-WO2021/156769,2021,A1Locationinpatent:Page/Pagecolumn114-115

ethyl2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropanoate

1401090-53-6

[1]CurrentPatentAssignee:SANOFI-WO2014/152215,2014,A1

[2]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[3]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[4]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[5]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[6]Zhao,Jin;Gimi,Rayomand;Katti,Sanjeev;Reardon,Michael;Nivorozhkin,Vitaly;Konowicz,Paul;Lee,Edward;Sole,Lynne;Green,Jerome;Siegel,CraigS.[OrganicProcessResearchandDevelopment,2015,vol.19,#5,p.576-581]

[7]Zhao,Jin;Gimi,Rayomand;Katti,Sanjeev;Reardon,Michael;Nivorozhkin,Vitaly;Konowicz,Paul;Lee,Edward;Sole,Lynne;Green,Jerome;Siegel,CraigS.[OrganicProcessResearchandDevelopment,2015,vol.19,#5,p.576-581]

[8]Zhao,Jin;Gimi,Rayomand;Katti,Sanjeev;Reardon,Michael;Nivorozhkin,Vitaly;Konowicz,Paul;Lee,Edward;Sole,Lynne;Green,Jerome;Siegel,CraigS.[OrganicProcessResearchandDevelopment,2015,vol.19,#5,p.576-581]

[9]CurrentPatentAssignee:SANOFI-US9126993,2015,B2

[10]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1

[11]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1

[12]CurrentPatentAssignee:SANOFI-US2017/334903,2017,A1

[13]CurrentPatentAssignee:SANOFI-US2017/334903,2017,A1

[14]CurrentPatentAssignee:SANOFI-WO2020/163337,2020,A1

[15]CurrentPatentAssignee:SANOFI-WO2020/163337,2020,A1

[16]CurrentPatentAssignee:SANOFI-WO2020/163244,2020,A1

[17]CurrentPatentAssignee:SANOFI-WO2020/163244,2020,A1

[18]CurrentPatentAssignee:SANOFI-WO2021/156769,2021,A1

[19]CurrentPatentAssignee:SANOFI-WO2021/156769,2021,A1

2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropanoicacid

1401090-53-6

[1]CurrentPatentAssignee:SANOFI-WO2014/152215,2014,A1

[2]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[3]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[4]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[5]Zhao,Jin;Gimi,Rayomand;Katti,Sanjeev;Reardon,Michael;Nivorozhkin,Vitaly;Konowicz,Paul;Lee,Edward;Sole,Lynne;Green,Jerome;Siegel,CraigS.[OrganicProcessResearchandDevelopment,2015,vol.19,#5,p.576-581]

[8]CurrentPatentAssignee:SANOFI-US9126993,2015,B2

[9]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1

[10]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1

[11]CurrentPatentAssignee:SANOFI-US2017/334903,2017,A1

[12]CurrentPatentAssignee:SANOFI-WO2020/163337,2020,A1

[13]CurrentPatentAssignee:SANOFI-WO2020/163244,2020,A1

[14]CurrentPatentAssignee:SANOFI-WO2021/156769,2021,A1

2-(2-(4-fluorophenyl)thiazol-4-yl)-N-hydroxy-2-methylpropanamide

1401090-53-6

[1]CurrentPatentAssignee:SANOFI-WO2014/152215,2014,A1

[2]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[3]CurrentPatentAssignee:SANOFI-WO2014/151291,2014,A1

[6]CurrentPatentAssignee:SANOFI-WO2016/145046,2016,A1

[7]CurrentPatentAssignee:SANOFI-WO2020/163337,2020,A1

[8]CurrentPatentAssignee:SANOFI-WO2020/163244,2020,A1

[9]CurrentPatentAssignee:SANOFI-WO2021/156769,2021,A1

Literature

Title: Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22.

Title: Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86-98.

Title: Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373(1):51-60. doi:10.1007/s00441-017-2704-y

Title: Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS